This article is more than 5 years old. Information may no longer be current.

VEGF Trap enters phase 1 trial for AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

TARRYTOWN, N.Y. — A drug that blocks vascular endothelial growth factor has begun phase 1 trials with administration by intravitreal injection in patients with age-related macular degeneration, according to its developer.

Regeneron Pharmaceutical’s VEGF Trap “blocks all forms of VEGF-A with extremely high affinity,” said Jesse M. Cedarbaum, MD, vice president of clinical affairs at Regeneron.

The phase 1 trial is a dose-escalating study designed to assess the safety and tolerability of intravitreal injection of VEGF Trap in patients with wet AMD, according to a press release. Patients will receive a single dose of the drug, delivered by intravitreal injection, and then will be evaluated for 3 months to measure the durability of effects and provide guidance for dosing regimens to be used in future trials, the release said.

Regeneron reported on an earlier phase 1 trial of systemic administration of the drug at the Association for Research in Vision and Ophthalmology meeting. That study showed a statistically significant decrease in excess retinal thickness that increased in both magnitude and duration with higher doses.